ClinicalTrials.gg
RecruitingNCT06830200Updated Sep 15, 2025

Peri-implantitis Treatment With Chitosan Brush

An interventional study of Non-surgical periodontal treatment with chitosan brush and Non-surgical treatment of pre-implantitis with titanium curette in Peri-implantitis, sponsored by Hacettepe University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Hacettepe University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 55 studies in Peri-Implantitis with a site in Turkey — 16 open to participants now, 19 under way, none of them phase 3. Peri-Implantitis · Turkey.

Planned enrollment
8th of 26
60 · median 50
Started
2025
with 7 others
No phase
26 of 55
10 open now
Primary completion
2026-12
later than 9 of 18 live
Registered
28th of 55
by date
Lead sponsor
3 of 55
Hacettepe University

Among the 55 studies in Peri-Implantitis with a site in Turkey, this one is the 8th largest by planned enrollment of the 26 interventional ones that give a count, is one of 8 that started in 2025, is one of 26 with no phase, reaches primary completion later than 9 of the 18 other live ones, and was the 28th registered.

Peri-Implantitis

324 studies on the registry are indexed under Peri-Implantitis; 89 are open to participants now.

Browse Peri-Implantitis studies →

Open to participants now

16 of the 55 studies in Peri-Implantitis with a site in Turkey are open now. Recruiting first, the newest first:

10 more — sign in →

All 16 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 50 Peri-Implantitis studies recruiting now, 28 (56%) set no upper age limit and 9 (18%) stop at 75 or younger; 7 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Peri-Implantitis with a site in Turkey, or all of them as a file.
02

Study summary

In dentistry, dental implant applications for tooth loss/deficiency are prominent and provide successful long-term results in terms of functionality and aesthetics. However, peri-implant diseases such as peri-implant mucositis and peri-implantitis may develop due to biofilm accumulation around the implant. In peri-implantitis, in addition to the clinical inflammation findings seen in peri-implant mucositis, there is also progressive bone loss. This condition is to be treated with non-surgical or surgical methods. Titanium curettes, ultrasonic instruments, laser systems, and chitosan brushes are used for biofilm removal in non-surgical treatment. Chitosan is a natural polysaccharide obtained from chitin. It is biocompatible, biodegradable, and has antibacterial activity. In addition, chitosan reduces the levels of IL-1β, IL-6, and TNF-α, which also play a role in the pathogenesis of peri-implantitis, and exhibits anti-inflammatory effects on macrophages activated by lipopolysaccharide. Although many methods are used to treat peri-implantitis, successful and predictable results cannot be obtained. This study aims to examine the clinical and immunological findings and observe the changes in the non-surgical treatment of peri-implantitis using chitosan brush or titanium curette over 12 months. Sixty dental implants diagnosed with peri-implantitis clinically and radiographically at the Department of Periodontics, Faculty of Dentistry, Hacettepe University will be included in the study. Non-surgical peri-implantitis treatment of these patients will be performed using a chitosan brush (N=30, case group) or titanium curette (N=30, control group). Pre-operative and post-operative 3rd, 6th, and 12th months, clinical periodontal indices will be recorded, peri-implant crevicular fluid (PIF) will be collected, and maintenance treatment will be applied to the patients. IL-1β, TNF-α, IL-8, IL-10, and IL-17 levels in the collected PIF will be determined by the ELISA method. The effectiveness of chitosan brush and titanium curette in treating peri-implantitis will be evaluated and compared clinically and immunologically.

03

Conditions studied

  • Peri-implantitis

Browse trials for

Keywords

  • Chitosan Brush
  • Non-Surgical Peri-implantitis Treatment
  • Peri-implantitis
  • Cytokine
  • Titanium Curette
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of peri-implantitis in an implant that has been in function for more than 12 months
  • Age ≥ 18 and \< 65
  • Agreeing to participate in the study after reading the form
  • Completion of periodontal treatment of patients diagnosed with periodontitis before inclusion in the study

Exclusion criteria

Exclusion Criteria:

  • Patients under 18 years of age
  • Patients who have received or are currently receiving radiotherapy, chemotherapy and long-term systemic treatment
  • Patients who received systemic antibiotics within 6 months from baseline
  • Pregnant or lactating patients
  • Patients with anatomical abnormalities around the implant (e.g., apically positioned implants adjacent to a tooth)
  • Patients with prostheses that prevent access for implant debridement with chitosan brushes or titanium curettes
  • Implants with an overdenture superstructure
  • Implants to be explanted
  • Patients with ≥ 3
  • Patients reporting reactions or adverse events to chitosan, stainless steel, adhesives, or polypropylene
  • Clinically mobile implants
  • Recently placed and non-osseointegrated implants
  • Around major nerves and blood vessels, if there is a risk of structural damage
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Chitosan Brush

    The implants in the chitosan brush group will be debrided with a chitosan brush dipped in sterile physiological saline solution using a rotary instrument system for 2 minutes. After mechanical treatment, the peri-implant pockets will be washed with sterile physiological saline solution. In cases with BOP+ and PD≥ 4 mm at 3 and 6 months after treatment, the treatment will be repeated in the same way as the previous one. Local infiltration anesthesia will be applied to the patients when deemed necessary. The prosthetic superstructures of the implants will not be removed for clinical examination or treatment. In cases where there is more than one implant in the same patient requiring peri-implantitis treatment, all of these implants will be included in the same treatment group.

    Procedure: Non-surgical periodontal treatment with chitosan brush

  • Active comparator
    Titanium Curette

    The implants in the titanium curette group will be treated with titanium curettes for 2 minutes. After mechanical treatment, the peri-implant pockets will be washed with sterile physiological serum. In cases with BOP+ and PD≥ 4 mm at 3 and 6 months after treatment, the treatment will be repeated in the same way as the previous one. Local infiltration anesthesia will be applied to the patients when deemed necessary. The prosthetic superstructures of the implants will not be removed for clinical examination or treatment. In cases where there is more than one implant requiring peri-implantitis treatment in the same patient, all of these implants will be included in the same treatment group.

    Device: Non-surgical treatment of pre-implantitis with titanium curette

Interventions

  • ProcedureNon-surgical periodontal treatment with chitosan brush

    Non-surgical treatment of pre-implantitis with chitosan brush

  • DeviceNon-surgical treatment of pre-implantitis with titanium curette

    Description: Non-surgical treatment of pre-implantitis with titanium curette

06

What researchers measure

Primary outcomes

  1. Probing Pocket Depth

    The distance between the mucosal margin and the bottom of the peri-implant pocket \[six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual and distolingual) on each implant\]

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  2. Radiographic Bone Level (RBL)

    RBL is determined in millimeters by metrically measuring the distance from the implant shoulder to the first bone-implant contact on the radiograph. Increasing RBL indicates worse outcome

    Time frame: From the baseline to the 12th month (Baseline, 6th, 12th months)

Secondary outcomes

  1. Gingival index (GI)

    According to the GI system; 0: Normal gingiva 1. Mild inflammation with no edema, color change or bleeding on probing in the gingiva 2. Moderate inflammation with redness, edema and brightness in the gingiva and bleeding on probing 3. Severe inflammation with significant redness, edema, ulceration and spontaneous bleeding. Six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual and distolingual) on each implant. The gingival index of an implant is calculated by dividing the total score of that implant by 4. Increased GI indicates worse outcome.

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  2. Plaque Index (PI)

    According to PI scores; 0: No plaque 1. Invisible film-like plaque attached to the free gingival margin and adjacent implant surface, detectable with a probe 2. Visible, moderate soft attachment within the gingival pocket or on the gingival margin and adjacent implant surface 3. Indicates the presence of dense soft attachment within the gingival pocket or on the gingival margin and adjacent implant surface. Six sites (mesiobuccal, buccal, distobuccal, mesiolingual, lingual and distolingual) were measured on each implant.The arithmetic average of 4 measurement values obtained from an implant is recorded as the PI score for that implant. Increased PI indicates worse outcome

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  3. Bleeding on Probing

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  4. Keratinized Mukoza Width

    The distance between the keratinized mucosa margin and the mucogingival junction in the mid-buccal region of the implant

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  5. Recession Depth

    The distance between the margin of the prosthetic restoration and the keratinized mucosal marjin

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  6. IL-1β

    From PIOS

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  7. TNF-α

    From PIOS

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  8. IL-8

    From PIOS

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  9. IL-10

    From-PIOS

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

  10. IL-17

    From PIOS

    Time frame: From the baseline to the 12th month (Baseline, 3rd, 6th, 12th months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Dec 2026, 19 months after the start.

Of 121 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 19 months is below that.

Counting every sponsor, half of 128 studies reached it within 26 months; a quarter within 12 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartActual
Apr 10, 2025
Primary completionEst.
Dec 1, 2026
CompletionEst.
Jun 1, 2027
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06830200
Responsible party
Buket Acar (Assistant Professor, Hacettepe University) — Principal investigator
First posted
Feb 17, 2025
Start date
Apr 10, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Sep 15, 2025

Study contacts

Buket Acar, PHD
Contact
dtbuketacar@gmail.com
+90 312 305 2217

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion